Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its ...

Revenue-- Revenue net of returns was $86,000, reflecting intentional reductions in ClearUp marketing and unit sales. Operating expenses-- Operating expenses were $2.0 million, up from $1.3 million in ...

Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million ...

As securities class action filings continue to rise in the First Circuit, courts in the District of Massachusetts are setting ...

The Vicksburg Police Department is accepting applications for entry-level officer positions. The department said it offers a ...

The case goes back to 2019, when two dealers got into a car accident in a small town outside Knoxville, Tennessee, according ...

Southwest Research Institute scientists and engineers have developed a custom large language model (LLM) to accelerate drug ...

On the last day of his visit to Singapore, Secretary for Health Prof Lo Chung-mau, leading a delegation, tours the National ...

PolyPid Ltd. (NASDAQ: PYPD) Q2 2025 Earnings Call Transcript August 13, 2025 PolyPid Ltd. misses on earnings expectations.

In this randomized, double-blind trial, Aligos Therapeutics is evaluating its investigational oral capsid assembly modulator ALG-000184 against tenofovir disoproxil fumarate in 200 treatment-naïve ...

Ronald W. McClurg, CFO, said, "product revenue increased 105% to $1.7 million" and cited "sizable improvements year-over-year ...